Quantel Medical Receives FDA Approval for the Vitra 2 Laser for Retinal Photocoagulation

Quantel Medical announced that it has received approval from the FDA for the Vitra 2 photocoagulator.

The Vitra 2 includes all the key elements of the Vitra photocoagulator and features a wide a range of improvements and new functionalities.

The Vitra 2 features a new generation of optimized laser cavity with an increased max power level. It is also now compatible with SingleSpot and MultiSpot technologies, according to a company news release. The device also features an easy-to-use clinically oriented software interface simplifying the treatment procedures and the doctors’ workflow thanks to printable treatment reports.

The Vitra 2 is compatible with Haag Streit and Zeiss types slit lamps with Quantel Medical YAG and YAG/SLT lasers, and can be connected to a wide range of delivery systems (operating microscopes, laser indirect ophthalmoscopes and laser probes).

“After a successful career spanning more than 13 years and with more than 3000 units sold worldwide, Quantel Medical is proud to announce the renewal of its 532nm flagship Vitra photocoagulator” Jean-Marc Gendre, CEO Quantel Medical, said in a company news release. “We are very excited to bring our new 532nm laser to ophthalmologists and their patients. Thanks to its flexibility and its ease of use, we are sure that more and more surgeons will embrace the MultiSpot technology delivery mode and its associated treatments benefits for retinal photocoagulation.”

The Vitra 2 laser was launched in Europe in 2018.